TOP2A and tuberculosis: We first evaluated resistance against the second-line anti-tuberculosis drug moxifloxacin, a DNA gyrase inhibitor, as resistance to this drug typically is based on well-defined mutations at specific positions in the gyrA and gyrB genes [21].